Page 1 of 1
New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)
Posted: Tue May 31, 2016 3:51 pm
by DK37
I think I have posted this MSS-eligible immunotherapy trial before but I noticed today that it has finally opened trial sites in the United States (previously it was Europe only) - so I wanted to repost. Your tumor needs to be CEA-positive. It combines a targeted form of IL-2 "RO6895882" (to activate the immune system in the vicinity of tumor) along with a PDL1 immunotherapy. It has trial locations in NYC and CT. I believe there can be a disconnect between CEA-expression on the tumor itself and what they measure floating in the blood stream - so I would not discard this trial possibility based upon bloodstream CEA results before talking to a MD at the trial.
https://clinicaltrials.gov/ct2/show/NCT ... 673&rank=1 -DK
Re: New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)
Posted: Thu Jun 02, 2016 5:21 pm
by juliej
DK37 wrote:I believe there can be a disconnect between CEA-expression on the tumor itself and what they measure floating in the blood stream - so I would not discard this trial possibility based upon bloodstream CEA results before talking to a MD at the trial.
You're right:
This study states : "The elevation of serum CEA and the expression of CEA in tissues did not show a direct correlation."
Re: New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)
Posted: Thu Jun 02, 2016 6:13 pm
by DK37
[quote="juliej"
You're right:
This study states : "The elevation of serum CEA and the expression of CEA in tissues did not show a direct correlation."[/quote]
Great eyes Juliej!!
Thanks!
-DK
Re: New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)
Posted: Thu Jun 02, 2016 9:14 pm
by Stanfordmom
Tom,
do you think this comb will work for KRAS mutant patients?
thanks,
Sha
Re: New MSS-Elegible PDL1 Combo Trial (RO6895882, CEA-targetted IL2)
Posted: Fri Jun 03, 2016 12:18 am
by DK37
Stanfordmom wrote:Tom,
do you think this comb will work for KRAS mutant patients?
thanks,
Sha
Hi Sha,
My guess is that KRAS-status won't matter. If this drug strategy works (unknown, being tested right now), my guess is that it would work similarly between KRAS-wildtype and KRAS-mutant.
-DK